STOCKS TELEGRAPH

Category: Morning News

  • Investor Optimism Surges As Aptorum Group (APM) Confirms Merger

    Investor Optimism Surges As Aptorum Group (APM) Confirms Merger

    After the announcement of a definitive merger agreement with DiamiR Biosciences, Aptorum Group Limited (NASDAQ: APM) shares were surging 298.02% as of the latest check to trade at $3.86.

    DiamiR, which has a CLIA-licensed and CAP-accredited facility in New Haven, Connecticut, is well-known for creating unique blood-based diagnostic tools that target brain health and other complicated disorders.

    All-Stock Merger to Create Synergistic Life Sciences Firm

    After the merger, DiamiR Biosciences will become a fully-owned subsidiary of Aptorum Group through an all-stock transaction. APM will continue to trade on the Nasdaq Stock Market, while DiamiR will keep its name despite the merger.

    After considering a number of strategic alternatives, Aptorum’s board of directors concluded that this transaction has the best chance of producing both short-term and long-term shareholder value.

    Aligning Strategically for International Growth

    According to Aptorum’s leadership, the integration of DiamiR’s expertise will position the combined entity to emerge as a globally focused life sciences company. The merged organization aims to generate revenue from biopharma services and deliver innovative biomarker panels designed to better characterize patients with complex biology, including those affected by neurodegenerative and autoimmune disorders.

    The partnership is expected to accelerate DiamiR’s clinical and pharmaceutical service offerings, with a strong emphasis on aging-related diseases such as Alzheimer’s.

    Merger Structure and Future Operations

    Prior to the merger’s closing, Aptorum will re-domicile to the state of Delaware. Post-domestication, APM will acquire all outstanding shares of DiamiR in exchange for newly issued common stock, resulting in DiamiR shareholders owning approximately 70% of the combined company.

    Existing Aptorum shareholders will retain the remaining 30%. The merged entity will establish its headquarters in Princeton, New Jersey. Five directors will make up its board: three will be chosen by APM, and two will be chosen by DiamiR, along with one board observer.

    Aptorum’s path to becoming a major force in non-invasive diagnostics and cutting-edge life sciences solutions has undergone a sea change with this strategic consolidation.

  • Strategic Partnership Drives Brazil Potash (GRO) Higher In Pre-Hour Trading

    Strategic Partnership Drives Brazil Potash (GRO) Higher In Pre-Hour Trading

    Brazil Potash Corp. (NYSE: GRO) experienced a significant uptick in share price during pre-market trading, with its stock rising 55.17% to $2.25. This rally follows the company’s announcement of a strategic collaboration through a non-binding Memorandum of Understanding (MOU) with Fictor & WTT S.A. (“Fictor Energia”), a division of the Brazilian private equity firm Fictor Group.

    Powering the Autazes Project

    The agreement paves the way for Fictor Energia to finance approximately $200 million in power transmission infrastructure for Brazil Potash’s Autazes Project. Under the MOU, Fictor Energia will undertake the full development, permitting, construction, and operation of transmission lines delivering 300MW annually—sourced from approximately 80% renewable Brazilian grid electricity.

    This will be executed under a Build, Own, Transfer (BOT) model, with asset ownership transferring to Brazil Potash after 25 years of operation.

    Equity Investment and Phased Commitments

    In addition to infrastructure financing, Fictor Energia has committed to a $20 million equity investment in Brazil Potash. This will be disbursed in two tranches: $2 million upon signing the definitive partnership agreement and the remaining $18 million following receipt of the power line installation license.

    This arrangement significantly reduces the capital burden on Brazil Potash’s construction budget, enabling better alignment with its long-term development objectives.

    Future Steps and Executive Appointment

    Both parties are now progressing toward the execution of definitive agreements. Fictor Energia will begin initial engineering and regulatory work immediately, although the MOU remains non-binding and subject to final documentation and approvals.

    If formalized, the power infrastructure is expected to be operational by July 2029, coinciding with the anticipated production launch of the Autazes Project. In parallel, Brazil Potash announced the appointment of Raphael Bloise as Interim President of Potassio do Brasil Ltda, the firm’s wholly owned Brazilian subsidiary.

  • Sonnet (SONN) Shares Surge on News of Transformational Business Deal

    Sonnet (SONN) Shares Surge on News of Transformational Business Deal

    Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares were surging 152.22% as of the last check in early trading today, reaching $13.04, following the announcement of a transformative business combination agreement.

    SONN revealed it has entered into a definitive Business Combination Agreement (BCA) with Rorschach I LLC and associated sponsors, setting the stage for a strategic shift in its corporate focus.

    Formation of Hyperliquid Strategies Inc. and Strategic Holdings

    Rorschach I LLC is a newly established entity affiliated with Atlas Merchant Capital LLC and Paradigm Operations LP. Through this agreement, Sonnet BioTherapeutics aims to reposition its business by creating a substantial reserve of HYPE—the token native to the Hyperliquid Layer-1 blockchain.

    The combined company will be known as Hyperliquid Strategies Inc. (HSI) after the deal closes. It is anticipated that it will have roughly 12.6 million HYPE tokens, which are worth about $583 million, along with $305 million in gross cash investments, for a total assumed closing value of $888 million.

    Notable Participation of Investors and Appointments to Leadership

    The deal is being backed by a number of renowned investors, including Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital. As a publicly traded cryptocurrency treasury company, HSI is expected to stay listed on the Nasdaq Capital Market with a new ticker symbol.

    Alongside the purchase, there will be changes in leadership: David Schamis, co-founder and CIO of Atlas, will be named CEO, and Bob Diamond, co-founder and CEO of Atlas, will be appointed Chairman. In addition, two of Sonnet BioTherapeutics’ current independent directors and former Boston Federal Reserve President Eric Rosengren will join the board.

    Private Placement and Biotech Development Continuation

    Sonnet BioTherapeutics will raise $5.5 million as part of the deal by issuing warrants and non-voting convertible preferred shares through a private placement. At the end of the placement, convertible notes worth $2.0 million that were issued in June 2025 will also convert. Along with expenses related to the company combination, the proceeds will be used to fund working capital, ongoing biotech development, and general corporate operations.

    With this deal, Sonnet BioTherapeutics is able to retain investing in its core biotech portfolio while taking advantage of prospects in the digital asset sector, marking a significant strategic shift for the firm.

  • HIVE Digital Shares Climb Pre-Market On Operational Advancements

    HIVE Digital Shares Climb Pre-Market On Operational Advancements

    As of the latest check, shares of HIVE Digital Technologies Ltd. (NASDAQ: HIVE) had increased by a substantial 7.75% pre-market on Thursday, reaching $2.50. The company’s revelation that it has doubled its worldwide Bitcoin mining hashrate from 6 EH/s at the start of 2025 to 12 EH/s has sparked the optimistic sentiment.

    At the same time, HIVE said that its operational performance had significantly improved, surpassing a yearly run rate revenue of $250 million.

    Growth and Strategy in Paraguay

    This achievement stems from HIVE’s substantial infrastructure development in Yguazú, Paraguay, where the company is making great strides toward constructing three campuses of data centers powered by hydropower. These state-of-the-art facilities are making Paraguay a global center for Bitcoin mining and renewable energy.

    HIVE has incorporated 1 EH/s of Bitmain S21+ Hydro ASIC miners in Phase 2 of development, with plans to grow up to 6.5 EH/s by the end of August. By the end of the summer, the business expects to attain 18 EH/s, and by Thanksgiving 2025, 25 EH/s.

    Strong Operational and Financial Results

    With a mining margin of over 55%, HIVE is already producing over 6 BTC every day and has already reached a $250 million yearly revenue run rate. The company expects to generate $400 million in yearly revenue with the expected 18 EH/s capability.

    In addition, HIVE wants to raise mining profits to over 60% and enhance fleet efficiency to 18.5 J/TH while taking current hashprice and electricity expenses into consideration.

    Industry Recognition

    The industry is taking notice of HIVE’s strong pace and creative execution in Paraguay. Along with providing real social advantages like better public lighting in Valenzuela and air conditioning systems at nearby schools, the project has also produced hundreds of local employment.

    HIVE’s projects are changing the standards for the deployment of digital infrastructure in developing nations by emphasizing sustainable development and community involvement.

  • Evoke Pharma (EVOK) Stock Soars Following Positive Patent News

    Evoke Pharma (EVOK) Stock Soars Following Positive Patent News

    A significant regulatory event led to a sharp increase in the share price of Evoke Pharma, Inc. (NASDAQ: EVOK). EVOK shares were up 162.78% at $6.99 as of the most recent market check. The dramatic increase comes after the business announced that the USPTO had granted it a Notice of Allowance for a new patent application that would cover the use of GIMOTI in patients with moderate to severe gastroparesis symptoms.

    New Patent Expands Intellectual Property Estate

    The authorized application greatly expands Evoke’s portfolio of intranasal metoclopramide-related intellectual property and is a continuation of U.S. Patent No. 11,517,545. The new patent is expected to be in effect until December 2036 when it is formally issued. Evoke Pharma also intends to register the patent in the FDA’s Orange Book, which is expected to extend GIMOTI’s market exclusivity beyond the term of current patents.

    Enhancing Protection and Patient Reach

    The GIMOTI brand views this development as a strategic step forward that strengthens both its target patient base and its mode of usage. For patients who suffer from delayed stomach emptying, which reduces the effectiveness of oral drugs, GIMOTI continues to show good potential as a non-oral option, according to Evoke. The business is still committed to broadening GIMOTI’s application and maximizing its medicinal advantages.

    Dedication to Ongoing Awareness and Innovation

    Evoke Pharma has filed a second continuation application to obtain expanded claims for therapies aimed at the same patient category, in keeping with its continuous innovation activities. Additionally, the organization is renewing its commitment to improve outcomes for individuals living with this chronic and frequently under-recognized illness by actively engaging in Gastroparesis Awareness Month this August.

    GIMOTI is still the only self-administered, non-oral, FDA-approved formulation of metoclopramide that is recommended for the treatment of acute and recurring diabetic gastroparesis in adults. It provides a vital alternative in cases when oral therapies may not be effective.

  • Wolfspeed (WOLF) Surges After Announcing New Finance Chief

    Wolfspeed (WOLF) Surges After Announcing New Finance Chief

    The announcement of a significant leadership appointment drove Wolfspeed, Inc.’s (NYSE: WOLF) stock price to leap 23.38% to $2.85 during the morning trading session. The stock price rise reflects strong investor confidence when the company named Gregor van Issum as its new CFO, effective September 1, 2025.

    An Accomplished Financial Strategist

    In order to maintain business continuity during the changeover, Interim CFO Kevin Speirits will stay on with the company until Van Issum takes over. Van Issum will work in Wolfspeed’s headquarters in Durham, North Carolina, and will answer directly to CEO Robert Feurle. He was appointed following a comprehensive internal and external search.

    With more than 20 years of expertise in financial leadership, Van Issum is known for spearheading significant financing and restructuring initiatives in the IT sector. In his prior roles, he guided companies through challenging operational and financial environments at semiconductor behemoths NXP Semiconductors N.V. and ams-OSRAM AG.

    Operational Proficiency in Superior Manufacturing

    Van Issum most recently held the positions of Group Controller and Executive Vice President of ams-OSRAM, a multibillion Euro corporation. In this capacity, he served as the Chief Transformation and Performance Officer and oversaw cost-cutting and revenue-generating projects. It is anticipated that his experience overseeing manufacturing processes worth billions of euros would help Wolfspeed scale its exclusive 200mm silicon carbide platform.

    Additionally, Van Issum played a critical role in mergers, acquisitions, and IT systems strategy at ams-OSRAM. His earlier tenure at NXP Semiconductors included leadership roles in secure identification and analog mixed signal segments.

    Leadership Restructure Positions Wolfspeed for Growth

    Van Issum’s appointment follows the recent onboarding of Dr. David Emerson as Wolfspeed’s first Chief Operating Officer in May. With highly skilled executives in both positions, the business hopes to improve its response to industry challenges and new possibilities while solidifying its position in the global silicon carbide market. WOLF’s dedication to long-term strategic development and market expansion is demonstrated by the leadership reorganization.

  • Apogee Therapeutics (APGE) Stock Rises In Pre-Market Session

    Apogee Therapeutics (APGE) Stock Rises In Pre-Market Session

    Following the announcement of positive clinical trial data, shares of Apogee Therapeutics, Inc. (NASDAQ: APGE) are rising rapidly. APGE’s stock was up 18.73% at $56.35 as of the most recent pre-market check. The revelation of 16-week findings from Part A of the Phase 2 APEX study assessing APG777, the company’s leading anti-IL-13 antibody candidate for moderate-to-severe atopic dermatitis (AD), served as the catalyst for the encouraging momentum.

    Revolutionary Effectiveness Proof

    By Week 16, two-thirds of patients taking APG777 had an EASI-75 response, according to Apogee Therapeutics (APGE). APG777 may be the best-in-class treatment for AD since it has the greatest EASI-75 response rate ever recorded in a worldwide study, both in topline data and when corrected for placebo. The compound’s potential to alter treatment standards by producing better clinical results with less frequent doses is highly supported by the research.

    Reaching Regulatory Milestones and Optimized Dosing

    Given that patients with higher levels of medication exposure had better results, the study findings supported the exposure-response connection of APG777. In order to improve dose levels, Part B of the APEX experiment is investigating these findings in more detail.

    Topline findings are expected in mid-2026, and about 280 people are being randomized to three dose groups or a placebo. Furthermore, Apogee Therapeutics is making headway against DUPIXENT in a head-to-head study (APG279), with effectiveness comparisons anticipated in the second half of 2026.

    Long-Term Dosing and Market Positioning

    In the Part A extension phase, Apogee Therapeutics (APGE) is also testing maintenance dose regimens of three and six months; findings are anticipated in early 2026. Based on only four injection days, the first 16-week data shows that APG777 has the potential to drastically lower the injection load without sacrificing efficacy.

    These results may provide significant advantages to patients, doctors, and payers in addition to its positive safety profile, confirming APG777’s promise as a game-changing treatment for AD.

  • Bone Biologics (BBLG) Stock Rallies Strongly In Pre-Hour Trading

    Bone Biologics (BBLG) Stock Rallies Strongly In Pre-Hour Trading

    During today’s pre-market session, shares of Bone Biologics Corporation (NASDAQ: BBLG) were showing a notable upward trend, rising 82.21% to $7.58 as of the last check. Significant business activities, including a significant patent application and an update on Nasdaq compliance, preceded the notable increase in BBLG’s stock value.

    A Patent Application Promotes Bone Treatment Innovation

    Bone Biologics (BBLG) has submitted a new patent application to the USPTO for its innovative NELL-1 protein technology. The application focuses on the potential therapeutic applications of recombinant human NELL-1 (rhNELL-1) polypeptide compositions to treat a variety of bone-related conditions.

    This scientific discovery represents a major turning point in Bone Biologics’ ongoing attempts to develop more potent treatments, particularly for patients having spinal fusion procedures. If granted, the patent will bolster BBLG’s intellectual property assets and long-term clinical development trajectory.

    Nasdaq Compliance Has Been Restored

    In a different statement, Bone Biologics stated that it is now in compliance with Listing Rule 5550(a)(2), which requires a minimum bid price, as required by the Nasdaq. The Nasdaq Stock Market LLC previously notified the business that its common stock now satisfies all requirements for continuing listing on the Nasdaq Capital Market.

    On April 7, 2025, Nasdaq first informed Bone Biologics that the firm was noncompliant after its shares had fallen below $1.00 per share for 30 straight working days. In order to fix this, BBLG has to keep the closing bid price at least $1.00 for ten consecutive trading sessions, a milestone Bone Biologics officially attained on June 24, 2025.

    Strategic Momentum and Investor Confidence

    Complete listing compliance and a possible patent filing are two events that show Bone Biologics’ strategic goals have advanced significantly. BBLG is positioned well within the biomedical innovation environment thanks to the notable stock rise, which reflects rising investor confidence in the company’s pipeline and operational prospects.

  • Ascent Solar (ASTI) Shares Rally On NASA Collaboration Announcement

    Ascent Solar (ASTI) Shares Rally On NASA Collaboration Announcement

    In intraday trading, Ascent Solar Technologies, Inc. (NASDAQ: ASTI) shares jumped 87.90% to $2.19, driven by the news of a major cooperative deal with NASA.

    Strategic Announcement

    With assistance from the NASA Glenn Research Center (GRC), Ascent Solar (ASTI) announced the start of work under a Collaborative Agreement Notice (CAN) with NASA’s Marshall Space Flight Center (MSFC). The goal of this collaboration is to use copper-indium-gallium-selenide (CIGS) photovoltaic (PV) modules to increase the capacity of receiving beamed electricity.

    Technology Development for Space Power Infrastructure

    The goal of the CAN effort is to expedite the development of commercial technology, particularly in the field of beamed power, to assist upcoming space missions. NASA will supply technical know-how and thorough testing, while Ascent Solar will offer design and prototype development.

    The partnership aims to reduce the cost, weight, and operational risk of conventional spacecraft power systems by delivering commercial-ready alternatives for distributed power in orbit during a 12-month timeframe.

    NASA Psyche Mission and Early Validation

    The viability of narrow-beam technology was confirmed by NASA’s 2023 Psyche Mission by successfully demonstrating deep space laser communications across a distance of 19 million miles. Building on that, NASA MSFC conducted bench tests in 2024 that verified Ascent’s commercial off-the-shelf PV products could effectively receive beamed power—setting the stage for this formal collaboration.

    Reducing Downmass for Planetary Missions

    Space exploration missions, particularly those targeting the Moon and beyond, are constrained by the heavy power generation systems required for surface mobility and operations.

    Ascent’s lightweight, thin-film solar technology could significantly reduce this “downmass,” with potential cost savings reaching millions of dollars per lander mission. The CAN’s technical goals include enhancing power output and ensuring durability through lunar nights and in permanently shadowed regions believed to contain water ice.

    Future Prospects for Lunar Facilities

    This public-private partnership is expected to support NASA in meeting its broader goals under the Commercial Lunar Payload Services (CLPS), prospective planetary missions, and the Artemis lunar campaign. It also backs international efforts under the Artemis Accords to construct scalable, sustainable infrastructure on the Moon.

    Thus, Ascent Solar’s (ASTI) advancements in thin-film PV technology in providing effectiveness, endurance, and affordability in challenging environments may be extremely advantageous for future missions.

  • Sequans (SQNS) Gains Pre-Hour Buzz With Bold Bitcoin Treasury Strategy

    Sequans (SQNS) Gains Pre-Hour Buzz With Bold Bitcoin Treasury Strategy

    After Sequans Communications S.A. (NYSE: SQNS) announced a bitcoin treasury strategy, the company’s shares jumped 15.54% in pre-market trading to $2.23. This daring move represents a strategic shift away from its conventional emphasis on the semiconductor cellular IoT market.

    Strategic Financing to Fund Bitcoin Initiative

    Sequans plans to use a combination of loan placements and private equity to generate about $384 million in total revenues. Approximately $189 million in convertible secured debentures and $195 million in equity instruments are part of the deal. In keeping with its view of bitcoin’s long-term potential as a robust and valued asset for shareholders, the business plans to create a bitcoin treasury, which this capital round will help to fund.

    Collaboration with Swan Bitcoin and Continued IoT Commitment

    Sequans plans to work with Swan Bitcoin, a pioneer in bitcoin treasury management systems, to carry out its bitcoin treasury effort. Sequans reaffirmed its commitment to its primary goal of developing 4G and 5G cellular IoT technology while welcoming this new course. The company maintains a strong product roadmap to support evolving IoT application demands and facilitate a smooth transition from 4G to 5G.

    Details of the Private Placement Offerings

    Sequans has concluded agreements for the sale of 1,392,857,140 ordinary shares (nominal value €0.01 per share), represented by 139,285,714 ADSs or pre-funded warrants, in addition to common warrants to purchase up to 208,928,460 ordinary shares (20,892,846 ADSs). The total cost of these instruments will be $0.14 per common share, or $1.40 each warrant and ADS.

    Convertible debentures for $189 million and further rights to buy up to 202,499,980 common shares (20,249,998 ADSs) have also been obtained by the firm. Within ninety days following their separate closings, the warrants from both placements can be exercised.

    Closing Timeline and Shareholder Approval

    The offering is anticipated to conclude on or around July 1, 2025, subject to the satisfaction of normal closing conditions and shareholder approval at Sequans’ June 30, 2025, general meeting.